# BPC-157 Dosage — Research Context Only

> Research-context dosage record for BPC-157: dose ranges, routes, durations, half-life, and pharmacokinetics from published animal studies. Not for human use. Not medical advice.

## Scope and Framing

This page is a research-context dosage record. It documents what was administered in published studies, at what quantities, via what routes, and for what durations. This information is presented for informational and research-literacy purposes only.

BPC-157 is not approved for human use by the FDA, EMA, or any other regulatory authority. The dose values below are reported exactly as they appear in the primary literature for rodent and in vitro models. They do not constitute dosing guidance for any purpose.

## Dose Ranges in Published Rodent Studies

Published BPC-157 rodent studies span seven orders of magnitude and consistently report active effects at the low end of that range.

**10 μg/kg/day intraperitoneal.** The most common systemic rodent dose. Used in wound healing, Achilles tendon, pulmonary hypertension, fistula, and quadriceps reattachment studies [2][4][8][12][15].

**10 ng/kg/day intraperitoneal.** Effective in Achilles tendon, pulmonary hypertension, fistula, and quadriceps reattachment models [2][8][12][15].

**10 pg/kg/day intraperitoneal.** The lowest dose level tested systematically. Active in Achilles tendon and wound healing studies [2][4]. No lethal dose established at 2 g/kg IV or intragastric in mice [11].

**0.1–0.5 μg/mL in vitro.** Used in isolated rat Achilles tendon fibroblast cultures; up to sevenfold GH receptor upregulation by day three [3].

**200 μg/kg single IP dose.** Used in the spinal cord compression model (with a 2 μg/kg arm; both doses produced comparable outcomes) [6].

**20 μg/kg intraperitoneal.** Used in lower-extremity ischemia-reperfusion remote organ protection study [14].

**Pharmacokinetic dose range (rats).** 20–500 μg/kg intramuscular; IV at 20 μg/kg [10].

**Pharmacokinetic dose range (dogs).** 6–150 μg/kg intramuscular; IV at 6 μg/kg [10].

**Oral / drinking water delivery.** Approximately 0.16 μg/mL or 0.16 ng/mL in rat drinking water (~12 mL/rat/day) [8][12][15].

## Routes of Administration

Nine routes appear across the published BPC-157 literature:

1. **Intraperitoneal (IP)** — most common [1][2][4][5][6][14]
2. **Intravenous (IV)** — pharmacokinetic studies and human safety pilot [10][13]
3. **Intramuscular (IM)** — pharmacokinetic studies in rats and dogs [10]
4. **Oral gavage** — quadriceps reattachment study (immediate post-surgical gavage) and wound healing study [4][12]
5. **Drinking water (ad libitum oral)** — pulmonary hypertension, fistula, and quadriceps reattachment studies [8][12][15]
6. **Topical cream (1 μg/g)** — wound healing and burn model [4]
7. **Local wound application** — vascular occlusion and fistula studies [9][15]
8. **Ophthalmic drops (2 pg–2 μg/mL)** — corneal neovascularization models [11]
9. **Intragastric gavage** — vascular occlusion studies [9]

Human routes documented in pilot studies: intra-articular (14 patients), intravesical (12 patients), and intravenous (2 volunteers) [13].

## Pharmacokinetics

**Plasma half-life.** Approximately 15.2 min in rats (IV); approximately 5.3 min in beagle dogs (IV). Very rapid clearance consistent with metabolic degradation into constituent amino acids [10].

**Intramuscular bioavailability.** 14–19% in rats; 45–51% in dogs [10].

**Metabolic clearance.** Metabolized into component amino acids via urine and bile pathways. Linear pharmacokinetics confirmed; no accumulation on repeated dosing [10].

**Oral bioavailability paradox.** Very low oral bioavailability in rats (pharmacokinetic study), yet efficacy is documented via oral delivery in multiple rodent models. BPC-157 demonstrates resistance to gastric acid degradation; local gastrointestinal tissue effects may not require significant systemic absorption. For tissues distant from the gut, the mechanism underlying oral efficacy is not definitively explained.

## Half-life and Duration of Effect

The plasma half-life of approximately 15 min (rat, IV) does not preclude sustained biological effects. Receptor-level and gene-expression-level changes — such as Egr1 and Akt1 upregulation documented within 10 minutes of BPC-157 application [4] — persist beyond plasma clearance. No accumulation was observed on repeated dosing [10].

Study durations span from single-dose protocols (spinal cord [6], organ protection [14]) to 90-day continuous oral dosing (quadriceps reattachment [12]).

## References

[2] Krivic A, et al. J Orthop Res. 2006. DOI: 10.1002/jor.20096.
[3] Chang CH, et al. Molecules. 2014. DOI: 10.3390/molecules191119066.
[4] Seiwerth S, et al. Front Pharmacol. 2021. DOI: 10.3389/fphar.2021.627533.
[6] Perovic D, et al. J Orthop Surg Res. 2019. DOI: 10.1186/s13018-019-1242-6.
[8] Udovicic M, et al. Biomedicines. 2021. DOI: 10.3390/biomedicines9070822.
[9] Sikiric P, et al. World J Gastroenterol. 2022. DOI: 10.3748/wjg.v28.i1.23.
[10] He L, et al. Front Pharmacol. 2022. DOI: 10.3389/fphar.2022.1026182.
[11] Sikiric P, et al. Pharmaceuticals. 2025. DOI: 10.3390/ph18060928.
[12] Matek D, et al. Pharmaceutics. 2025. DOI: 10.3390/pharmaceutics17010119.
[13] McGuire FP, et al. Curr Rev Musculoskelet Med. 2025. DOI: 10.1007/s12178-025-09990-7.
[14] Demirtas H, et al. Medicina. 2025. DOI: 10.3390/medicina61020291.
[15] Vukusic D, et al. J Physiol Pharmacol. 2024. DOI: 10.26402/jpp.2024.1.09.
[16] Yuan C, et al. Int J Mol Sci. 2026. DOI: 10.3390/ijms27062876.

---

For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.